Abstract:
Objective: To determine the efficacy and safety of Citicoline in acute stroke.
Study Design: Comparative cross-sectional study.
Place of Study and Duration: Combined Military Hospital, Jhelum Pakistan, from Dec 2017 to May 2018.
Methodology: Thirty patients with a new onset of stroke, either ischemic or hemorrhagic, were included in the study. This sample of the population was further categorized into four Groups based on the National Institute of Health Stroke Scale scoring system. Half of the patients were medicated with Citicoline and standard stroke treatment and were examined as cases. The rest of the patients were treated with standard stroke management alone and were examined as Controls. The baseline guidelines of the patients were assessed by the Canadian Neurological Stroke Scale. However, for ease of comparison, the CNSS was converted into the National Institute of Health Stoke Scale using the following formula: NIHSS=23-2xCNSS.
Results: In our study, baseline improvement in NIHSS score was higher in the Citicoline Group than in the Control Group(68% in the case Group vs. 53% in the Control Group). There was a 30% drop in NIHSS score in Cases compared to the ControlGroup (p>0.05).
Conclusion: This study could not prove the effectiveness of Citicoline despite a favourable improvement in NIHSS score in cases. Though Citicoline is a well-tolerated and safe drug, it is ineffective in improving neurological outcomes in patients with acute stroke.
